Focused on creating novel therapies against diseases where the unmet medical need exists.

Our Pipeline

Clinical and Pre-Clinical Programs


Our Products

CiVi 030

CiVi 030 is an intravenous formulation of iloprost, a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc). 

CiVi 007

CiVi 007 is a third generation PCSK9 antisense molecule being developed as an oral treatment for hypercholesterolemia and the prevention of atherosclerotic cardiovascular disease.  

CiVi 020

CiVi 020 is a potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. PPARδ is a ligand activated transcription factor that exerts tissue specific control of genes involved in energy utilization.